NCT01955564View on ClinicalTrials.gov

A Phase I- Sequential Cohort Dosing to Determine Maximum Tolerated Dose in Healthy Male Volunteers.

PHASE1CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

September 30, 2014

Study Completion Date

February 28, 2015

Conditions
Schizophrenia
Interventions
DRUG

NW-3509a

single dose

Trial Locations (1)

90806

Collaborative Neuroscience Network-Clinical Pharmacology Unit, Long Beach

Sponsors
All Listed Sponsors
lead

Newron Pharmaceuticals SPA

INDUSTRY

NCT01955564 - A Phase I- Sequential Cohort Dosing to Determine Maximum Tolerated Dose in Healthy Male Volunteers. | Biotech Hunter | Biotech Hunter